Phase II study of weekly docetaxel in patients with metastatic breast cancer

Annals of Oncology

Volumn 13, Issue 2, 2002, Pages 286-292

  Aihara, T ^a   Kim, Y ^a   Takatsuka, Y ^a  

^a KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

Breast cancer; Chemotherapy; Docetaxel; Phase II

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOCETAXEL; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; FLUSHING; FRACTURE; GASTROINTESTINAL SYMPTOM; HEARING DISORDER; HUMAN; HYPERSENSITIVITY REACTION; LEG EDEMA; LIVER DYSFUNCTION; MEDICAL ASSESSMENT; METASTASIS; NAIL DISEASE; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; STOMACH MUCOSA LESION; STOMATITIS; TASTE DISORDER; TREATMENT FAILURE;

EID: 0036302586     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf027     Document Type: Article

References (22)

1. Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group
2. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer
3. -2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC
4. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group
5. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
6. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
7. A late phase II study of RP56976 (docetaxel) in patients with advanced of recurrent breast cancer
8. Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK
9. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC
10. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients
11. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: The French compassionate use programme experience
12. Docetaxel
13. Early clinical studies with docetaxel
14. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
15. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
16. Activity of weekly Taxotere (TXT) in patients with metastatic breast cancer
17. Weekly docetaxel for patients with recurrent breast cancer: Clinical results and pharmacokinetic/ pharmacodynamic assessment
18. Docetaxel administered on a weekly basis for metastatic breast cancer
19. Weekly docetaxel in patients with advanced malignancies. Toxicity profile and activity results
20. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer
21. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study